Source: Annual Congress 2001 - Small cell lung cancer therapy



Rating:

Share or cite this content

Citations should be made in the following way:
P. Remiszewski, J. Slodkowska, B. Roszkowska, E. Decker, M. Marzinek, E. Rowiñska-Zakrzewska (Warsaw, Poland). Myocardial infarction (MI) as a cause of death in patients treated for small cell lung cancer (SCLC). Eur Respir J 2001; 16: Suppl. 31, 2698

Member's Comments

No comment yet.

Related content which might interest you: Two-stage treatment of non-small cell lung cancer (NSCLC) in patients with severe coronary heart disease. Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 Use of Bode index (BI) in patients with COPD undergoing inpatient pulmonary rehabilitation (IPR) after lung resection (LR) for non small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 70s Year: 2006 Causes of death in inoperable non small cell lung cancer (NSCLC)-retrospective study Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Small cell lung cancer in patients with elderly Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC) Source: International Congress 2019 – Treatment of lung cancer Year: 2019 How to predict fatal pneumonitis in non-small cell lung cancer (NSCLC) patients treated with radiotherapy (RT) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Cancer recurrence in surgically treated non small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 755s Year: 2006 Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Tissue factor induced tumor vascular infarction in lung cancer Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018 C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002 European treatment guidelines: small cell lung cancer (SCLC) Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Causes of death in patients operated for lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 173s Year: 2005 Small cell lung cancer (SCLC) in Norway. A population-based study Source: Annual Congress 2008 - Actual challenges in thoracic surgery Year: 2008 LATE-BREAKING ABSTRACT: A mRNA signature predicts outcome of patients (pts) with advanced non small cell lung cancer (NSCLC) treated with cisplatin (C) and vinorelbine (V): A ELCWP prospective study Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Efficacy and safety of amurubicin (AMR) for the elderly with refractory relapse small cell lung cancer (SCLC) who had previous treatment Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Myocardial infarction, heart failure and mortality in patients with COPD in primary care. Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009